Intech Investment Management LLC Has $13.65 Million Stock Position in Amgen Inc. $AMGN

Intech Investment Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 48,364 shares of the medical research company’s stock after acquiring an additional 4,375 shares during the quarter. Intech Investment Management LLC’s holdings in Amgen were worth $13,648,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the second quarter worth about $27,000. Evelyn Partners Investment Management LLP acquired a new position in Amgen during the 2nd quarter worth approximately $32,000. Howard Hughes Medical Institute bought a new position in Amgen in the 2nd quarter valued at approximately $32,000. Quaker Wealth Management LLC boosted its position in Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC bought a new stake in shares of Amgen during the third quarter worth $34,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $379.33 on Friday. The company’s fifty day simple moving average is $347.68 and its 200 day simple moving average is $318.76. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $387.49. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market cap of $204.48 billion, a price-to-earnings ratio of 26.66, a PEG ratio of 3.81 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMGN. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Leerink Partners increased their target price on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Barclays began coverage on Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. Argus upped their price objective on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Finally, Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $351.76.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an all-time intraday high, reflecting strong investor demand and momentum that likely supported upward price pressure earlier in the session. Amgen stock hits all-time high
• Positive Sentiment: Amgen is featured in dividend-stock roundup articles, which can attract long-term income-focused buyers and support demand for shares given its yield and payout profile. Got $10,000? Put It in These Dividend Stocks Now
• Neutral Sentiment: Commentary pieces note Amgen has outpaced the Dow over the past year, providing a positive performance backdrop — but analysts remain cautious, suggesting upside may be tempered by valuation and execution risks. Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Legislative risk: S.3847 (Stop Corporate Inversions Act of 2026) was flagged as potentially relevant to multinationals including AMGN; the bill would tighten rules around inversion tax treatment — a longer-term policy item to monitor but not an immediate earnings driver. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported spikes in short interest appear in the feed but show zero shares/NaN in the figures — this looks like a data or reporting error rather than a meaningful change in positioning; still worth checking official exchange short-interest releases for confirmation.
• Negative Sentiment: A small institutional holder (Bradley Foster & Sargent) trimmed its position (~1,336 shares), a minor selling signal that may slightly contribute to sell-side flow but is not materially large versus Amgen’s market cap and average volume. Bradley Foster & Sargent Inc. CT Sells 1,336 Shares

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.